Unknown

Dataset Information

0

Belimumab in systemic lupus erythematosus.


ABSTRACT: Systemic lupus erythematosus (SLE) is one of the most challenging autoimmune disorders with a complex pathophysiology and diverse clinical presentation. Many drugs have been used to treat SLE with suboptimal results, especially in patients with moderate-to-severe disease. Belimumab is the first biological drug to be approved for the treatment of SLE in more than 50?years. This monoclonal antibody blocks B-cell activating factor, a cytokine important for B-cell differentiation and survival. In this review we focus on the activity of belimumab in patients with SLE and discuss the controversies of its use.

SUBMITTER: Vilas-Boas A 

PROVIDER: S-EPMC4612697 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Belimumab in systemic lupus erythematosus.

Vilas-Boas Andreia A   Morais Sandra A SA   Isenberg David A DA  

RMD open 20150303 1


Systemic lupus erythematosus (SLE) is one of the most challenging autoimmune disorders with a complex pathophysiology and diverse clinical presentation. Many drugs have been used to treat SLE with suboptimal results, especially in patients with moderate-to-severe disease. Belimumab is the first biological drug to be approved for the treatment of SLE in more than 50 years. This monoclonal antibody blocks B-cell activating factor, a cytokine important for B-cell differentiation and survival. In th  ...[more]

Similar Datasets

| S-EPMC3513897 | biostudies-literature
| S-EPMC8246766 | biostudies-literature
| S-EPMC11340010 | biostudies-literature
| S-EPMC8602678 | biostudies-literature
| S-EPMC5349337 | biostudies-literature
| S-EPMC9314515 | biostudies-literature
| S-EPMC6171800 | biostudies-literature
| S-EPMC7769209 | biostudies-literature
| S-EPMC7278961 | biostudies-literature
| S-EPMC9434316 | biostudies-literature